Steven Kyle Boyd Buys 25,000 Shares of OraSure Technologies (NASDAQ:OSUR) Stock

OraSure Technologies, Inc. (NASDAQ:OSUR) Director Steven Kyle Boyd purchased 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 14th. The stock was purchased at an average price of $2.99 per share, for a total transaction of $74,750.00. Following the acquisition, the director owned 113,462 shares of the company’s stock, valued at $339,251.38. The trade was a 28.26% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Steven Kyle Boyd also recently made the following trade(s):

• On Tuesday, May 12th, Steven Kyle Boyd acquired 25,000 shares of OraSure Technologies stock. The shares were purchased at an average cost of $2.98 per share, with a total value of $74,500.00.

OraSure Technologies Stock Performance

OraSure Technologies stock traded down $0.09 during trading hours on Thursday, reaching $2.95. 868,088 shares of the company’s stock traded hands, compared to its average volume of 535,873. The firm has a market capitalization of $203.11 million, a price-to-earnings ratio of -2.84 and a beta of 0.89. OraSure Technologies, Inc. has a fifty-two week low of $2.08 and a fifty-two week high of $3.82. The firm’s 50 day moving average is $3.06 and its 200-day moving average is $2.76.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings results on Wednesday, February 25th. The medical instruments supplier reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.02). OraSure Technologies had a negative return on equity of 18.57% and a negative net margin of 66.42%.The business had revenue of $26.76 million for the quarter, compared to analyst estimates of $26.44 million.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Altai Capital Management L.P. raised its stake in OraSure Technologies by 73.4% during the 3rd quarter. Altai Capital Management L.P. now owns 3,748,836 shares of the medical instruments supplier’s stock worth $12,034,000 after buying an additional 1,586,488 shares during the period. Peapod Lane Capital LLC grew its stake in OraSure Technologies by 51.1% in the fourth quarter. Peapod Lane Capital LLC now owns 1,018,470 shares of the medical instruments supplier’s stock valued at $2,465,000 after acquiring an additional 344,437 shares during the period. Tudor Investment Corp ET AL bought a new stake in shares of OraSure Technologies in the third quarter worth about $808,000. Cannell Capital LLC increased its holdings in shares of OraSure Technologies by 12.6% in the third quarter. Cannell Capital LLC now owns 2,099,815 shares of the medical instruments supplier’s stock worth $6,740,000 after acquiring an additional 234,826 shares in the last quarter. Finally, IMC Chicago LLC acquired a new stake in shares of OraSure Technologies during the first quarter worth about $71,000. Institutional investors own 93.50% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded OraSure Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, May 7th. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Reduce” and an average target price of $3.00.

About OraSure Technologies

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.